GSK’s Witty: China Moving Rapidly To ‘No Growth’ Status

Despite a first-quarter slump, GSK insists its China business is moving back to underlying growth, although the firm’s CEO warns the country's overall pharma market has "slowed down dramatically" and is moving quickly to "no-growth" status.